Analyzing Clinical Outcomes and Genomic Data of American Indian Patient Population
Running, not enrolling
Conditions studied: Immune Checkpoint Inhibitors, Metastatic Solid Tumor, Nonsmall Cell Lung Cancer, Melanoma, Renal Cell Carcinoma, Gastrointestinal Cancer, Squamous Cell Carcinoma
In brief
The aim of this study is to describe the outcomes in American Indian patients receiving immunotherapy in a multi-institution retrospective study at several other high-volume centers that care for this patient population and to identify any healthcare disparities that can lead to future interventional studies.
Key facts
- Study ID
- NCT05863052
- Run by
- University of Oklahoma
- People needed
- 72
- Starts
- 2022-01-31
- Expected to finish
- 2027-12-01
- Last updated by the study team
- 2026-02-10
Who can join
Age: 18 and older, up to 99. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- above age 18,
- histologically and cytologically confirmed NSCLC, melanoma, head and neck squamous cell carcinoma, gastrointestinal cancers,, renal cell carcinoma, or any other solid tumors where immune checkpoint therapy has been used
- received immunotherapy as part of their treatment
- Self-identified American Indian in ethnicity
- Patients at the Stephenson Cancer Center between 2015 to 2021
You may not qualify if…
- patients who did not receive immune checkpoint inhibitor therapy
Where it is running
- Arizona Cancer Center at the Unvieristy of Arizona — Tucson, Arizona, United States
- University of New Mexico Comprehensive Cancer Center — Albuquerque, New Mexico, United States
- Stephenson Cancer Center — Oklahoma City, Oklahoma, United States
- Monument Health Cancer Care Institute — Rapid City, South Dakota, United States
- Avera Cancer Institute — Sioux Falls, South Dakota, United States
- Huntsman Cancer Institute at the University of Utah — Salt Lake City, Utah, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.